预约演示

更新于：2026-05-13

Lintuzumab Ac-225

更新于：2026-05-13

概要

概要

基本信息

药物类型

抗体偶联核素、治疗用放射药物

别名

225Ac-anti-CD33、225Ac-lintuzumab、Ac-225-Lintuzumab

+ [21]

靶点

CD33

作用方式

抑制剂

作用机制

CD33抑制剂(髓系细胞表面抗原CD33抑制剂)

治疗领域

肿瘤血液及淋巴系统疾病神经系统疾病+ [3]

在研适应症

成人急性髓性白血病CD33阳性急性髓性白血病难治性急性髓细胞白血病+ [6]

非在研适应症

急性早幼粒细胞白血病加速期慢性骨髄性白血病难治性贫血伴原始细胞过多+ [2]

原研机构

PDL BioPharma, Inc.

在研机构

National Cancer Institute

Actinium Pharmaceuticals, Inc.

非在研机构

Seagen, Inc.

权益机构

The Trustees of Columbia University in The City of New York

上海雅培制药有限公司

National Cancer Institute

+ [2]

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

使用我们的ADC技术数据为新药研发加速。

或

查看完整样例数据

Sequence Code 123485L

来源: *****

Sequence Code 12982042H

来源: *****

关联

项与 Lintuzumab Ac-225 相关的临床试验

NCT06802523

/ Suspended临床1期IIT

A Phase I Study of Lintuzumab-Ac-225 in Combination With Venetoclax and ASTX-727 in Adults With Newly Diagnosed AML

This phase I trial tests the safety, side effects, and best dose of lintuzumab-Ac225 in combination with venetoclax and ASTX-727, and how well they work in treating patients with newly diagnosed acute myeloid leukemia (AML). Lintuzumab-Ac225 is a monoclonal antibody, called lintuzumab, linked to a radioactive agent called actinium Ac 225. Lintuzumab attaches to CD33 positive cancer cells in a targeted way and delivers actinium Ac 225 to kill them. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. ASTX-727 is a combination of two drugs, cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Giving lintuzumab-Ac225 in combination with venetoclax and ASTX-727 may be safe and tolerable in treating patients with newly diagnosed AML and may improve the chance of going into remission and staying in remission for a longer period of time.

开始日期2026-04-21

申办/合作机构

National Cancer Institute

CTRI/2024/11/076470

/ Not yet recruiting临床1/2期

Study of Safety and Tolerability of Lintuzumab-Ac225 in combination with pembrolizumab or nivolumab in adult patients with locally advanced and metastatic non-small cell lung cancer (NSCLC) or Squamous cell cancer of the head and neck (HNSCC) - nil

开始日期2024-11-30

申办/合作机构

Actinium Pharmaceuticals, Inc.

NCT03932318

/ Withdrawn临床1/2期

A Phase I/II Study of Venetoclax and Azacitidine and Lintuzumab-Ac225 in Patients With Refractory or Relapsed AML

The study is a multicenter, open label Phase I/II trial.
1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 when given in combination with venetoclax and azacitidine for patients with CD33 positive AML. (Phase I portion)
2. To assess the percentage of patients with CR, CRh, CRi, MLFS or Overall Response (CR + CRh + CRi + MLFS), up to 6 months after the start of treatment without receiving other AML therapies.. (Phase 2 portion)

开始日期2023-03-01

申办/合作机构

Actinium Pharmaceuticals, Inc.

100 项与 Lintuzumab Ac-225 相关的临床结果

登录后查看更多信息

100 项与 Lintuzumab Ac-225 相关的转化医学

登录后查看更多信息

100 项与 Lintuzumab Ac-225 相关的专利（医药）

登录后查看更多信息

项与 Lintuzumab Ac-225 相关的文献（医药）

2025-04-01·LEUKEMIA

Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia

Article

作者: Abedin, Sameem M ; Chen, Mary M ; Desai, Avinash G ; Rotibi, Mojisola ; Guru Murthy, Guru Subramanian ; Runaas, Lyndsey ; Michaelis, Laura C ; Vusirikala, Madhuri ; Atallah, Ehab L ; Harrington, Alexandra ; Syed, Umar ; Gauger, Katelyn ; Hamadani, Mehdi ; Li, Kate L ; Carlson, Karen-Sue

Lintuzumab-Ac255 is a humanized anti-CD33 antibody linked to Actinium-225 delivering high-energy alpha-particles to leukemia cells, inciting double-strand DNA breaks and cell death. This phase 1 study assessed the safety and efficacy of lintuzumab-Ac225 after CLAG-M salvage therapy in patients with relapsed/refractory acute myeloid leukemia (R/R AML). Primary objectives were determination of maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and safety. Using a 3 + 3 dose-escalation design, 21 patients were enrolled sequentially into 4 cohorts to receive a lintuzumab-Ac225 infusion (0.25-1.0 µCi/kg) 7 ( + 2) days after CLAG-M (days 1-6); 5 additional patients received the RP2D. Of evaluable patients, 86.7% had high-risk disease. The MTD and RP2D was 0.75 µCi/kg. Common grade 3/4 adverse events were febrile neutropenia (65.4%) and decreased white blood cells (50%). The composite complete remission (CRc) rates (CR/CRi) were 56.6% overall, 50% in patients with mutated TP53, and 38.5% in prior venetoclax-treated patients. Measurable residual disease (MRD)-negativity was achieved in 8 of 12 responders. Among all patients (n = 26), estimated 2-year OS was 23.1% (95% CI, 9.4-40.3) and estimated 1-year PFS was 30.8% (95% CI, 14.6-48.5). Lintuzumab-Ac225 plus CLAG-M was well tolerated with expected, manageable toxicities, while yielding deep and meaningful responses in high-risk R/R AML patients.

2022-05-13·Clinical cancer research : an official journal of the American Association for Cancer Research

Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab

Article

作者: McDevitt, Michael R. ; Douer, Dan ; Larson, Steven M. ; Rosenblat, Todd L. ; Pandit-Taskar, Neeta ; Frattini, Mark G. ; Park, Jae H. ; Scheinberg, David A. ; Jurcic, Joseph G. ; Maslak, Peter G. ; Carrasquillo, Jorge A. ; Cicic, Dragan

Abstract:

Purpose::

The anti-CD33 antibody lintuzumab has modest activity against acute myeloid leukemia (AML). To increase its potency, lintuzumab was conjugated to actinium-225 (225Ac), a radionuclide yielding 4 α-particles. This first-in-human, phase I trial was conducted to determine the safety, pharmacology, and biological activity of 225Ac-lintuzumab.

Patients and Methods::

Eighteen patients (median age, 64 years; range, 45–80) with relapsed or refractory AML received a single infusion of 225Ac-lintuzumab at activities of 18.5 to 148 kBq/kg.

Results::

The maximum tolerated dose was 111 kBq/kg. Dose-limiting toxicities included myelosuppression lasting > 35 days in one patient receiving 148 kBq/kg and death from sepsis in two patients treated with 111 and 148 kBq/kg. Myelosuppression was the most common toxicity. Significant extramedullary toxicities were limited to transient grade 3 liver function abnormalities. Pharmacokinetics were determined by gamma counting serial whole blood, plasma, and urine samples at energy windows for the 225Ac daughters, francium-221 and bismuth-213. Two-phase elimination kinetics were seen with mean plasma t1/2 − α and t1/2 − β of 1.9 and 38 hours, respectively. Peripheral blood blasts were eliminated in 10 of 16 evaluable patients (63%) but only at doses of ≥ 37 kBq/kg. Bone marrow blasts were reduced in 10 of 15 evaluable patients (67%), including 3 patients with marrow blasts ≤ 5% and one patient with a morphologic leukemia-free state.

Conclusions::

Therapy for AML with the targeted α-particle generator 225Ac-lintuzumab was feasible with an acceptable safety profile. Elimination of circulating blasts or reductions in marrow blasts were observed across all dose levels.

2019-12-01·Journal of medical imaging and radiation sciences

Targeted Alpha-Particle Therapy for Hematologic Malignancies

Review

作者: Jurcic, Joseph G

INTRODUCTION:

The short range and high linear energy transfer of α-particles offer the potential for efficient tumor killing while sparing surrounding normal cells. Hematologic malignancies are ideally suited to targeted α-therapy because of easy accessibility of malignant cells in blood and bone marrow and their radiosensitivity.

METHODS:

A series of clinical trials were conducted to assess the safety and antileukemic effects of lintuzumab, an anti-CD33 antibody, labeled with the α-emitters bismuth-213 (²¹³Bi) and actinium-225 (²²⁵Ac) in patients with acute myeloid leukemia (AML).

RESULTS:

Initial studies showed that ²¹³Bi-lintuzumab had antileukemic activity and could produce remissions after partial cytoreduction with cytarabine. A phase I trial demonstrated that a single infusion of ²²⁵Ac-lintuzumab could be given safely at doses up to 111 kBq/kg with antileukemic activity at all dose levels studied. A second phase I study showed that 28% of older patients with untreated AML had objective responses after receiving fractionated-dose ²²⁵Ac-lintuzumab and low-dose cytarabine. A phase II study of ²²⁵Ac-lintuzumab monotherapy in this population produced remissions in 69% of patients receiving two fractions of 74 kBq/kg and 22% of patients receiving two 55.5-kBq/kg fractions.

CONCLUSIONS:

Studies with ²¹³Bi-lintuzumab provided proof of principle for systemically administered α-particle therapy. ²²⁵Ac-lintuzumab was active against advanced AML and produced remissions in older patients with untreated AML in combination with low-dose cytarabine and as a single agent. These studies provide the rationale for development of ²²⁵Ac-lintuzumab in combination with a variety of agents in AML and in other hematologic malignancies such as myelodysplastic syndrome and multiple myeloma.

项与 Lintuzumab Ac-225 相关的新闻（医药）

2026-05-06

·PRNewswire

Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization

– ATNM-400 in NSCLC: New data demonstrates ATNM-400's potential in KRAS-mutated models supporting its development as a mutation-agnostic therapy in settings where resistance to EGFR- and KRAS-targeted agents remains a major clinical challenge – ATNM-400 in prostate cancer: New data further supports ATNM-400 as a potential treatment option across the spectrum of PSMA-high, PSMA-low, and PSMA-negative disease, addressing a key limitation of PSMA-targeted therapies – Radioconjugation platform: New data demonstrates that optimizing chelator-to-antibody ratio (CAR) improves tumor targeting, internalization, and pharmacokinetics of 225Ac-labeled antibodies, directly supporting ATNM-400 development and reinforcing a proprietary radiochemistry capability that underpins Actinium's broader pipeline NEW YORK, May 6, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the upcoming presentation of three abstracts at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, taking place May 30-June 2, 2026, in Los Angeles, California. The presentations include two posters on ATNM-400, Actinium's first-in-class Actinium-225 (225Ac) antibody radioconjugate, demonstrating its potential in prostate cancer and non-small cell lung cancer (NSCLC), as well as a third poster presenting preclinical radiochemistry data on chelator-to-antibody ratio (CAR) optimization that underpins ATNM-400 development. Together, the data underscore Actinium's scientific leadership in next-generation alpha-emitting radioconjugates. Sandesh Seth, Actinium's Chairman and CEO, said, "Data to be presented at SNMMI 2026 further strengthen the profile of ATNM-400 as a first-in-class, radiotherapy with broad solid tumor applicability. In NSCLC, ATNM-400 demonstrates the ability to overcome key resistance mechanisms to both EGFR and KRAS mutations that limit current targeted therapies and support its development as a mutation agnostic agent. In prostate cancer, new data demonstrate its potential in the PSMA negative setting, in addition to promising data in PSMA-high and medium settings further supporting the differentiated profile of ATNM-400. Importantly, as we head toward clinical studies with ATNM-400, we showcase our efforts to maximize ATNM-400's therapeutic index by utilizing our deep radiochemistry expertise to optimize the CAR. Together, the data to be presented support ATNM-400's growing potential as a differentiated radiotherapy across multiple high-value solid tumor indications that represent some of oncology's largest commercial opportunities." ATNM-400 SNMMI 2026 Presentation Details Abstract Title: ATNM-400: A First-in-Class Actinium-225 Antibody Radioconjugate Demonstrating Potent PSMA-Independent Efficacy in Prostate Cancer Models Session: Oncology: Discovery & Translational Meet the Author Session Date & Time: Tuesday, June 2, 2026 11:30am-12:15pm PT | Los Angeles, California Abstract Title: ATNM-400: A First-in-Class Actinium-225 Antibody Radioconjugate Demonstrating Durable, Mutation-Agnostic Anti-Tumor Activity in Non-Small Cell Lung Cancer Models Session: Oncology: Discovery & Translational Meet the Author Session Date & Time: Tuesday, June 2, 2026, 11:30am-12:15pm PT | Los Angeles, California Abstract Title: Optimizing Chelator-to-Antibody Ratio Improves Tumor Targeting and Pharmacokinetics of 225Ac-Labeled Antibodies Session: MTA05 RPSC/CMIIT POPs and Science Pavilion Mixer Date & Time: Sunday, May 31, 2026, 7:30-8:00pm PT | Los Angeles, California About Actinium Pharmaceuticals, Inc. Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit . Forward-Looking Statements This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time. Investors: [email protected] SOURCE Actinium Pharmaceuticals, Inc. 21% more press release views with Request a Demo

放射疗法

2026-04-22

·PRNewswire

Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting

Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies including revumenib (menin-KMT2A inhibitor), gilteritinib (FLT3 inhibitor), and azacitidine (hypomethylating agent) - three pillars of modern AML treatment - supporting its potential role as a universal combination backbone Transcriptional reprogramming identified as a central mechanism showing that Actimab-A combinations don't just add cytotoxicity, they reprogram AML cells from proliferation toward differentiation and apoptosis, providing the mechanistic basis for deeper, more durable MRD-negative responses and reinforcing Actimab-A's role as a universal combination backbone across AML Robust cytotoxicity observed in primary AML patient samples across key mutations (FLT3, KMT2A, NPM1, IDH1, IDH2, or TP53), reinforcing Actimab-A's potential as a mutation-agnostic backbone therapy, complementing the manageable safety profile of Actimab-A observed across prior clinical trials in over 150 AML patients NEW YORK, April 22, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association for Cancer Research (AACR) Annual Meeting supporting transcriptional reprogramming as a central mechanism driving the mutation-agnostic anti-leukemic activity of Actimab-A (lintuzumab-Ac225) in acute myeloid leukemia (AML). GSEA shows Actimab-A combinations drive coordinated transcriptional reprogramming in AML: suppression of MYC, E2F, and G2/M proliferative programs alongside activation of p53 stress and apoptosis pathways. Lintuzumab-Ac225 Combination with SOC Enhances Cytotoxicity in Primary AML Patient Samples

AACR会议

2026-04-06

·PRNewswire

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

New data underscoring the potential of ATNM-400 as a first-in-class Ac-225 radioconjugate with broad pan-tumor efficacy across multiple solid tumor models Actimab-A demonstrates mutation-agnostic efficacy and a novel mechanism that enhances response to standard AML therapies Multiple data catalysts for ATNM-400 and Actimab-A in 2026; and posters for each to be presented on April 21, 2026 at AACR 2026 in San Diego, CA NEW YORK, April 6, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the publication of two abstracts that will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, California. The Company will present previously undisclosed data demonstrating the expanding potential of its Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies. Both presentations will occur on April 21, 2026 in the session Radiopharmaceutical Platforms for Theranostic Precision Oncology. Sandesh Seth, Actinium's Chairman and CEO, said, "These new data further validate the strength and versatility of our Ac-225 radiotherapy platform. ATNM-400 continues to show compelling pan-tumor activity, including activity in tumors resistant to current targeted therapies, supporting its potential as a first-in-class asset in large solid tumor indications. In parallel, Actimab-A's newly identified mechanism of transcriptional reprogramming provides important insight into its mutation-agnostic activity and ability to enhance standard-of-care therapies. Together, these findings reinforce our strategy to build a differentiated pipeline with multiple value-driving opportunities." ATNM-400 AACR 2026 Presentation Details Poster Number: 5824 Session: Radiopharmaceutical Platforms for Theranostic Precision Oncology Date & Time: April 21, 2026 – 2:00 PM – 5:00 PM PT | Poster Section 16, Board #18 Actimab-A AACR 2026 Presentation Details Poster Number: 5827 Session: Radiopharmaceutical Platforms for Theranostic Precision Oncology Date & Time: April 21, 2026 – 2:00 PM – 5:00 PM PT | Poster Section 16, Board #21 About Actinium Pharmaceuticals, Inc. Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit . Forward-Looking Statements This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time. Investors: [email protected] SOURCE Actinium Pharmaceuticals, Inc. 21% more press release views with Request a Demo

AACR会议

100 项与 Lintuzumab Ac-225 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Lintuzumab Ac-225	-	DB15053

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
成人急性髓性白血病	临床2期	美国	Actinium Pharmaceuticals, Inc.	2020-01-15
CD33阳性急性髓性白血病	临床2期	美国	Actinium Pharmaceuticals, Inc.	2020-01-15
难治性急性髓细胞白血病	临床2期	美国	Actinium Pharmaceuticals, Inc.	2020-01-15
急性髓性白血病	临床2期	美国	Seagen, Inc.	2007-09-01
胶质母细胞瘤，IDH野生型	临床1期	-	National Cancer Institute	2026-06-28
神经胶质肉瘤	临床1期	-	National Cancer Institute	2026-06-28
复发性胶质母细胞瘤	临床1期	-	National Cancer Institute	2026-06-28
复发性胶质瘤	临床1期	-	National Cancer Institute	2026-06-28
急性早幼粒细胞白血病	临床1期	美国	National Cancer Institute	2026-04-21
难治性多发性骨髓瘤	临床1期	美国	Actinium Pharmaceuticals, Inc.	2016-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2023	临床1/2期	难治性急性髓细胞白血病	18	Lintuzumab-Ac225	鑰願齋窪願艱網鹹襯齋(範壓製製選壓構齋憲範) = 鑰糧鹹獵選鏇構蓋襯願夢鹽壓鬱遞積蓋鬱繭鹹 (夢製觸鏇構製淵鏇襯選 ) 更多	-	2023-12-09
NCT03441048 (ASCO 12023 \| ASCO 22023) 人工标引	临床1期	难治性急性髓细胞白血病	19	Lintuzumab-Ac225+Cladribine+Cytarabine+Filgrastim+Mitoxantrone (High-risk population)	觸壓廠餘簾鹹窪簾餘網(窪製網膚繭齋窪製醖獵) = 鹹鬱積蓋鬱廠廠築窪顧淵窪鹹觸糧壓鏇鹹艱積 (憲簾獵鏇遞蓋膚製齋襯 ) 更多	积极	2023-05-26
NCT03441048 (ASCO 12023 \| ASCO 22023) 人工标引	临床1期	难治性急性髓细胞白血病	19	Lintuzumab-Ac225+Cladribine+Cytarabine+Filgrastim+Mitoxantrone (ELN Adv Risk)	觸壓廠餘簾鹹窪簾餘網(窪製網膚繭齋窪製醖獵) = 窪艱醖鏇窪積鑰構壓窪淵窪鹹觸糧壓鏇鹹艱積 (憲簾獵鏇遞蓋膚製齋襯 ) 更多	积极	2023-05-26
ASH 12022 \| ASH 22022 人工标引	临床1期	急性髓性白血病 MRD Negative	21	Cladribine+Cytarabine+Mitoxantrone Hydrochloride+[225Ac]-Lintuzumab	繭築範窪構構夢築遞網(衊鹽齋繭鹹獵膚簾願獵) = 憲膚範範衊衊壓餘膚顧築窪蓋淵膚鹹築艱襯構 (積構夢夢顧繭鑰製窪膚 ) 更多	积极	2022-11-15
SNMMI2017	N/A	未经治疗的小儿急性非淋巴细胞白血病	-	225Ac-lintuzumab	製鹽積築廠鏇繭願襯願(夢鏇廠鹽製願襯鹽膚遞) = Two patients had dose-limiting toxicity (grade 4 thrombocytopenia with marrow aplasia for > 6 weeks following therapy), one each in the 37 and 74 kBq/kg/fraction cohorts 網鹹鬱構壓積憲觸夢鹹 (網築襯範獵廠鹹廠襯簾 ) 更多	-	2017-05-24
NCI-2014-01360 (ASCO2015) 人工标引	临床1期	急性髓性白血病	12	LDAC+actinium-225 -lintuzumab	艱鹹鏇淵網襯鹹願齋淵(製餘淵餘鬱鹽糧鹹鹹艱) = one patient at 1 µCi/kg/fraction who had grade 4 thrombocytopenia and marrow aplasia > 6 wks after therapy 積積憲獵顧鑰襯鹹網觸 (範簾繭窪構顧鑰願餘醖 ) 更多	积极	2015-05-20